News and Events

Stay up to date on our progress.

December 9, 2024

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test …

READ MORE »
October 14, 2024

MyOme and Broad Clinical Labs to Support Southern Research Program to Bring Genetics-Driven Health Insights to Alabamians Free of Charge

Initiative to Empower the Underserved Community of Patients and Providers with Access to Personal Health Risks and Actionable Information to Prevent or Treat Disease…

READ MORE »
November 2, 2023

MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting

Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories and for South Asian individuals…

READ MORE »
March 16, 2023

MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Genomics Annual Meeting

Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical…

READ MORE »
February 22, 2023

MyOme, Natera Show Cross-Ancestry Polygenic Risk Score Improves Breast Cancer Prediction -GenomeWeb

From GenomeWeb: 'NEW YORK – Personalized genomics company MyOme's cross-ancestry, integrated risk score (caIRS) improved breast cancer prediction over the standard Tyrer-Cuzick (T-C) model…'

READ MORE »
February 22, 2023

MyOme Announces Publication of a Validated Cross-Ancestry Polygenic Risk Score for Breast Cancer

Data demonstrates improved breast cancer risk prediction across multiple ancestries over standard of care…

READ MORE »
October 27, 2022

MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment

Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries…

READ MORE »
June 21, 2022

MyOme Secures $23M in Series B Funding to Deliver Clinical Whole Genome Insights to Help Families Manage Risk for Inherited Diseases

The oversubscribed series B financing led by Healthcare Venture Partners, added SoftBank Corp. and Natera to existing investors– Sequoia Capital, Foresite Capital, Founders Fund, …

READ MORE »
June 16, 2022

Equity Issues, Admixed Populations Continue to Complicate Use of Polygenic Risk Scores — GenomeWeb

A dearth of genome-wide association studies focused on non-European populations, plus issues related to applying polygenic risk scores in populations with multiple ancestries, has spurred…

READ MORE »
June 15, 2022

MyOme Develops Cross-Ancestry Breast Cancer Polygenic Risk Score, Plans Product Launch — GenomeWeb

NEW YORK – Personalized genomics company MyOme presented data at the recent American Society of Clinical Oncology conference demonstrating its ability to train and validate…

READ MORE »
June 1, 2022

MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast Cancer

MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast CancerStudy highlights potential of Polygenic Risk Scores (PRS) to improve breast…

READ MORE »
April 6, 2022

Is it time to test embryos for common diseases? — MedicalXpress.com

A Silicon Valley company has designed a technique to decipher the genetic code of a tiny embryo and calculate its future risk of cancer, diabetes…

READ MORE »
footer logo
linkedin

© 2024 MyOme.com

MyOme is not responsible for the content or accuracy of third-party websites

The MyOme Personal Genome™ Report was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). College of American Pathologists (CAP) accredited and CLIA certified. ©2024 MyOme, Inc. All Rights Reserved.